LAGEVRIO

This brand name is authorized in Japan, New Zealand, Romania, United Kingdom, United States

Active ingredients

The drug LAGEVRIO contains one active pharmaceutical ingredient (API):

1 Molnupiravir UNII YA84KI1VEW - MOLNUPIRAVIR

Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. Molnupiravir is a prodrug that is metabolised to the ribonucleoside analogue N-hydroxycytidine (NHC) which distributes into cells where it is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP). Read about Molnupiravir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LAGEVRIO Hard capsule	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AB18		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Discover more medicines within J05AB18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: JP	医薬品医療機器総合機構	Identifier(s): 6250051M1028
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 23123
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68372001
Country: US	FDA, National Drug Code	Identifier(s): 0006-5055